Introduction
NAD+ (nicotinamide adenine dinucleotide) has emerged as one of the most intensively studied molecules in aging and metabolic research. While NAD+ itself is not a peptide, the compounds used to elevate NAD+ levels — including precursors and related peptide-adjacent research chemicals — represent an important category in the research landscape. This overview covers NAD+ biology, the major research compounds used to study it, and current research directions.
What Is NAD+ and Why Does It Matter?
NAD+ is a coenzyme found in all living cells that plays a central role in energy metabolism (as a hydride carrier in glycolysis, the TCA cycle, and the electron transport chain) and in cellular signaling as a substrate for sirtuins (longevity-associated deacetylases), PARP enzymes (DNA repair), and CD38 (a major NAD+-consuming enzyme). NAD+ levels decline with age in multiple tissues, and this decline has been linked to age-related functional deterioration in metabolism, DNA repair capacity, mitochondrial function, and cellular stress responses.
NAD+ Precursors in Research
The primary research compounds for elevating NAD+ levels are biosynthetic precursors that enter the NAD+ salvage or Preiss-Handler pathways. The most studied are: Nicotinamide Riboside (NR), a nucleoside that enters the salvage pathway via NRK1/2 enzymes; Nicotinamide Mononucleotide (NMN), a nucleotide one step closer to NAD+ in the pathway; and Niacin (nicotinic acid), which enters through the Preiss-Handler pathway. NR and NMN have the most extensive current preclinical and clinical research literature.
5-Amino-1MQ: A Novel NAD+ Research Tool
5-Amino-1-methylquinolinium (5-Amino-1MQ) represents a newer class of NAD+ research tool. Rather than serving as a precursor that boosts NAD+ synthesis, 5-Amino-1MQ is a small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that diverts nicotinamide away from NAD+ synthesis toward methylation. By inhibiting NNMT, 5-Amino-1MQ increases the availability of nicotinamide for NAD+ synthesis. Animal studies have shown effects on adipogenesis, fat mass reduction, and metabolic rate, positioning it as a compound of interest in obesity and metabolic disease research.
Sirtuin Research
A major focus of NAD+ research is the sirtuin family of NAD+-dependent deacetylases, particularly SIRT1 and SIRT3, which have been linked to metabolic regulation, DNA repair, and longevity signaling in model organisms. Research has sought to determine whether NAD+ elevation through precursor supplementation is sufficient to activate sirtuin pathways meaningfully in mammalian aging models.
Mitochondrial Research
NAD+ is essential for mitochondrial function, and declining NAD+ is associated with mitochondrial dysfunction in aging tissues. Research has shown that NAD+ precursor supplementation can restore mitochondrial morphology and function in aged animal models, supporting the hypothesis that NAD+ decline contributes causally to age-related metabolic deterioration.
Clinical Research Status
Multiple human clinical trials have examined NR and NMN supplementation for safety and NAD+ elevation efficacy. Both have been shown to safely and dose-dependently elevate blood NAD+ levels in humans. Functional health outcome data from clinical trials is still accumulating, with active trials in aging, cardiovascular disease, and metabolic conditions.
Conclusion
The NAD+ research landscape is one of the most active in aging and metabolic science. Precursor compounds NR and NMN dominate clinical research while newer tools like 5-Amino-1MQ offer alternative mechanistic approaches to NAD+ elevation. Understanding the biochemistry of NAD+ metabolism is essential for interpreting results across this rapidly evolving research field.